| BIO Chief: “Reckless” Executive Order on Drug Prices Threatens Innovation | Dan Stanton | 09/17/20 | Boston |
| FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy | Sarah de Crescenzo | 08/07/20 | National |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More | Frank Vinluan | 08/02/19 | National |
| White House Floats Canadian Import Plan But Excludes Many Costly Drugs | Frank Vinluan | 07/31/19 | National |
| Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More | Ben Fidler | 07/26/19 | National |
| Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More | Frank Vinluan | 06/21/19 | National |
| Bluebird Bio Sets $1.8M Price on Gene Therapy for Rare Blood Disease | Frank Vinluan | 06/14/19 | Boston |
| Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More | Frank Vinluan | 05/31/19 | National |
| Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More | Alex Lash | 05/24/19 | National |
| Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More | Frank Vinluan | 05/17/19 | National |
| Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More | Frank Vinluan | 04/26/19 | National |
| Can We Afford to Be Cured? A Conversation With ICER’s Steve Pearson | Alex Lash | 04/23/19 | Boston |
| Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More | Alex Lash | 04/12/19 | National |
| Senators Grill Pharmacy Benefit Execs About Skyrocketing Drug Prices | Frank Vinluan | 04/09/19 | National |
| Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More | Frank Vinluan | 04/05/19 | National |
| Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More | Frank Vinluan | 03/15/19 | National |
| Drug-Price Watchdog ICER Dives into Trump-Fueled Pharma Rebate Debate | Alex Lash | 03/13/19 | National |
| Two Years and Done: FDA Commissioner Gottlieb To Resign | Alex Lash | 03/05/19 | National |
| Lilly to Launch “Authorized Generic” Insulin Priced at 50% Discount | Frank Vinluan | 03/04/19 | Indiana |
| Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away | Alex Lash | 02/26/19 | National |
| Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More | Frank Vinluan | 02/01/19 | National |
| Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More | Frank Vinluan | 01/11/19 | National |
| Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More | Alex Lash | 01/11/19 | National |
| Bio Roundup: Eli Lilly Tries Tau, Generic Insulin, NASH Cash & More | Frank Vinluan | 12/14/18 | National |
| Amgen Slashes Cholesterol Drug Price 60% to Match Rival Regeneron | Frank Vinluan | 10/24/18 | National |
| Report: Express Scripts Shuts Out Teva Migraine Drug, Prefers Rivals | Frank Vinluan | 10/17/18 | National |
| Bio Roundup: Pfizer’s Rare Results, U.K.’s CAR-T No, IPO Go-Go & More | Alex Lash | 08/31/18 | National |
| Bio Roundup: Alnylam’s Moment, Read on Rebates, Skinny Plans & More | Alex Lash | 08/03/18 | National |
| Bio Roundup: Pfizer’s Prices, Novartis Cuts, Gene Therapy Guide & More | Frank Vinluan | 07/13/18 | National |
